Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

686
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
686
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

619
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

874
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
874
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

541
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
541
Group Therapy01:26

Group Therapy

439
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
439

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sarcoidosis with Cardiac Involvement and Monoclonal Gammopathy].

Kardiologiia·2020
Same author

[Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers].

Kardiologiia·2019
Same author

Kardiologiia·2019
Same authorSame journal

[A CASE OF FAMILIAL PULMONARY AND HEPATIC ECHINOCOCCOSIS)].

Klinicheskaia meditsina·2018
Same author

[Exacerbation of chronic obstructive pulmonary disease: the role of the molecular genetic method for the identification of pathogenic agents].

Klinicheskaia meditsina·2018
Same author

[EFFICIENT TREATMENT OF CHRONIC RESPIRATORY INSUFFICIENCY IN PATIENTS WITH KYPHOSCOLIOSIS].

Klinicheskaia meditsina·2016

Related Experiment Video

Updated: Feb 4, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K

[MODERN APPROACH TO THERAPY OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS].

O A Tsvetkova, O O Voronkova, O E Buyanova

    Klinicheskaia Meditsina
    |October 11, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Idiopathic pulmonary fibrosis (IPF) was treated using pirfenidone and nintedanib. This case report discusses the therapeutic roles of these antifibrotic medications in IPF management.

    More Related Videos

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
    06:29

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

    Published on: May 5, 2023

    3.1K
    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    1.8K

    Related Experiment Videos

    Last Updated: Feb 4, 2026

    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    1.1K
    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
    06:29

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

    Published on: May 5, 2023

    3.1K
    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    1.8K

    Area of Science:

    • Pulmonology
    • Pharmacology
    • Pathogenesis Research

    Background:

    • Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible lung disease with limited treatment options.
    • Understanding the pathogenesis of IPF is crucial for developing effective therapeutic strategies.
    • Pirfenidone and nintedanib are approved antifibrotic agents targeting key pathways in IPF.

    Observation:

    • This report details the treatment of a patient diagnosed with idiopathic pulmonary fibrosis.
    • The patient received a combination of pirfenidone and nintedanib for their IPF condition.
    • The clinical course and response to this dual therapy were monitored.

    Findings:

    • The combination therapy of pirfenidone and nintedanib was administered to the patient.
    • The study references the current understanding of IPF pathogenesis in relation to the treatment.
    • The report highlights the role of these specific medications in the patient's therapeutic regimen.

    Implications:

    • This case provides insights into the use of dual antifibrotic therapy in IPF.
    • The findings may contribute to refining treatment protocols for idiopathic pulmonary fibrosis.
    • Further research is warranted to explore the long-term efficacy and safety of combined pirfenidone and nintedanib in IPF.